---
title: "Did Merck (MRK) Beat Q3 2026 Estimates? Profit Returns After Two Loss Quarters"
canonical_url: https://www.stockexpertai.com/journal/2026-10-30/did-merck-mrk-beat-q3-2026-estimates-profit-returns-after-two-loss-quarters-535539f40dcd
last_updated: 2026-10-30T16:31:08.873Z
section: "Earnings Watch"
author: "Stock Expert AI Research"
publisher: Stock Expert AI
tickers: MRK
content_type: journal-article
---

# Did Merck (MRK) Beat Q3 2026 Estimates? Profit Returns After Two Loss Quarters

_Merck's third-quarter 2026 adjusted EPS of 2.49 beat the 2.09 estimate, and operating margin returned to 40.6% after losses in the first two quarters of the year._

![Did Merck — Journal cover](/public-objects/streetnews/2026-10-30/EARNINGS_WATCH-cover-a4e5afb7.jpg)
Stock Expert AI data cover: figures from Financial Modeling Prep.
Photo credit and licence on the image

Merck & Co. (NYSE: MRK) reported third-quarter 2026 adjusted earnings of 2.49 per share on Oct. 29, 2026, against an analyst estimate of 2.09, on revenue of $18.09B versus an estimate of $17.33B. Revenue was higher than the $17.18B a year earlier, but net income was lower. The bigger story is the swing: Merck went from operating losses in the first two quarters of 2026 to a 40.6% operating margin, and raised the midpoint of its full-year guidance.

*Figures are current as of Oct. 30, 2026 and cover the quarter ended Sept. 30, 2026, unless stated otherwise.*

## Key facts

- **Oct. 29, 2026:** Merck reported adjusted EPS of 2.49 vs an estimate of 2.09 (+$0.40, or 19.1% above the estimate) for the third quarter ended Sept. 30, 2026.
- **Revenue:** $18.09B vs an estimate of $17.33B (+$754.2M, 4.4% above the estimate). That is 5.2% higher than the $17.18B in the third quarter of 2025.
- **Net income:** $5.07B, down 12.4% from $5.79B a year earlier. Diluted EPS on that basis was 2.04, vs 2.32 a year earlier.
- **Operating margin:** 40.6% in the quarter ended Sept. 30, 2026, vs 43.4% in the quarter ended Sept. 30, 2025.
- **Oct. 30, 2026:** The stock traded at 149.58 USD, up 2.22% on the day. The 52-week range is 82.01-156.92 USD.

| Metric (Q3, ended Sept. 30) | 2026 | 2025 or estimate |
|---|---|---|
| Adjusted EPS | 2.49 | 2.09 (estimate) |
| Revenue | $18.09B | $17.33B (estimate); $17.18B year-ago |
| Operating income | $7.33B | $7.46B year-ago |
| Net income | $5.07B | $5.79B year-ago |
| Diluted EPS | 2.04 | 2.32 year-ago |

Why two EPS figures? The 2.49 figure is the one compared with analyst estimates, and it is the figure FMP lists as the reported result. The 2.04 figure is diluted EPS from the quarterly financial statements, which is the one to compare with the year-ago 2.32. The company said the 2.49 includes a charge of $0.12 per share related to the Ceybrion license agreement. Its non-GAAP results exclude other items it cited, such as acquisition-related charges and restructuring costs.

## What happened

Revenue beat the estimate, and the company pointed to newer products. According to the call, WINREVAIR (a pulmonary arterial hypertension drug), WELIREG (a cancer drug) and the under-the-skin version of KEYTRUDA, called KEYTRUDA QLEX, all made growing contributions. KEYTRUDA itself, the company's biggest product, kept growing on use in earlier-stage cancers and in cervical, breast, and head and neck cancers. Gardasil, the HPV vaccine, rose on a significant purchase by the U.S. CDC and on price. Animal health grew modestly, led by pets.

CEO Robert Davis said: "This momentum extends across multiple therapeutic areas and modalities and there is much more to come."

One item flatters the quarter. Management said favorable U.S. customer purchase timing helped third-quarter sales by about $550M. Of that, $200M related to KEYTRUDA and $50M to WINREVAIR, and both are expected to unwind in full in the fourth quarter. A further $300M related to vaccines, predominantly Gardasil: $50M should unwind in the fourth quarter and the remaining $250M in 2027. So part of the beat is pulled forward from later periods.

Operating expenses rose on launch and pipeline spending, partly offset by cost-optimization work and external funding for a TROP2 cancer program.

### The margin swing

The angle that matters most is how profit moved across 2026. The first two quarters were losses, and the table below shows the recovery.

| Quarter ended | Revenue | Operating margin | Net income |
|---|---|---|---|
| Sept. 30, 2025 | $17.18B | 43.4% | $5.79B |
| Dec. 31, 2025 | $16.32B | 37.7% | $2.96B |
| March 31, 2026 | $16.29B | -11.6% | -$4.24B (a loss) |
| June 30, 2026 | $16.61B | -4.1% | -$1.33B (a loss) |
| Sept. 30, 2026 | $18.09B | 40.6% | $5.07B |

Revenue was fairly flat through the first half of 2026, so the losses in those quarters did not come from weak sales. Gross margin stayed between 70.5% and 81.9% across all five quarters, and it was 81.4% in the latest one. The gap opened below the gross profit line. What drove the first-quarter and second-quarter losses is not identified in our sources.

On cash, the latest full cash flow data in our feed is for the quarter ended June 30, 2026: operating cash flow of $5.37B and free cash flow (cash left after capital spending) of $4.48B. In that quarter Merck paid $2.14B in dividends and $757.0M in buybacks. A year earlier, in the quarter ended June 30, 2025, free cash flow was $2.53B, so it rose year over year. We do not yet have the third-quarter 2026 cash flow statement.

## Why it matters for investors

**Guidance rose.** Management narrowed 2026 revenue guidance to between $66.8 billion and $67.3 billion and raised the midpoint. It guided full-year EPS to $2.77 to $2.82, which includes about $0.15 from currency and the Ceybrion charge, and again raised the midpoint. It also expects gross margin of about 81% and roughly $3 billion in share repurchases this year.

**The valuation looks high on trailing numbers, but the first-half losses weigh on them.** Trailing-12-month P/E (price divided by the last year of earnings) is 152.61, and net margin is only 3.6%, because the first-half losses sit inside that window. Price/free cash flow is 22.97 and the dividend yield is 2.3%. Compared with peers:

| Company | P/E (trailing) | Net margin |
|---|---|---|
| Merck (MRK) | 152.61 | 3.6% |
| AbbVie (ABBV) | 83.48 | 9.8% |
| Amgen (AMGN) | 29.10 | 22.9% |
| AstraZeneca (AZN) | 27.94 | 17.0% |
| Gilead (GILD) | -55.60 | -12.5% |

Merck's trailing P/E is the highest of the group, but the first-half losses make it a poor guide to how the business is priced today.

**Analysts lean positive.** Of 38 ratings, 26 are buy, 11 are hold and 1 is sell, for a consensus of "Buy". Analyst price targets average 159.95 USD (median 165.00 USD), ranging from a low of 105.00 USD to a high of 180.00 USD. The stock at 149.58 USD sits below the average target but inside the range. FMP's own discounted cash flow model, which estimates what future cash is worth today, gives 174.43 USD. That is a model output, not a forecast from us.

**Our MoonshotScore is 76.1 (Strong).** Stock Expert AI's score rates Merck against its sector on five pillars:

- Momentum: 88
- Quality: 88
- Growth: 74
- Valuation: 46
- Safety: 32

In plain terms, the business and price trend score well, while valuation is middling and safety is the weak spot. The safety score fits the balance sheet: as of June 30, 2026, total debt was $53.91B against cash and short-term investments of $7.14B, and debt/equity is 1.29. Other health checks are mixed to fine: a Piotroski score of 6 out of 9 and an Altman Z of 4.00.

## What could go wrong

- **KEYTRUDA's slowdown.** CFO Caroline Litchfield said: "We do expect Keytruda to continue to be an important contributor to our overall revenues although we do see growth moderating, and that is as we have reached peak penetration in a number of indications." She described the coming loss of patent protection as "more of a hill" with a shallow revenue dip.
- **2027 headwinds.** Management expects moderate top-line growth in 2027, with more than $2 billion of headwinds from generic competition for BRIDION, the Januvia family and Adempas, and underlying operating expenses rising at a mid to high single digit rate. Litchfield called it "another year of investment". She also said some consensus estimates reflect this messaging and others do not, so estimates may move.
- **Vaccines.** The company cited "increased hesitancy and reduced utilization," and U.S. sales of CAPVAXIVE fell.
- **Pricing and policy.** Management flagged pressure on pricing outside the U.S. and policy dynamics in Germany.
- **Litigation.** A Dutch court issued an injunction on KEYTRUDA QLEX in several European markets. Davis said it lasts "until the hearing is held" and does not speak to the merits, and that Merck is confident in its intellectual property. Merck says it is working to overturn the ruling and is not supplying six European markets for now, which management described as smaller-volume markets.
- **Law-firm notice.** A plaintiffs' law firm announced on Oct. 29, 2026 that it is investigating possible securities claims tied to a company disclosure on Oct. 22, 2026. An investigation announcement is not a finding of wrongdoing.
- **Insider selling.** Among the 30 most recent insider filings, those in the last 90 days show 0 open-market purchases and 11 sales. Insider sales are common and can have many causes.

## What to watch next

- **Fourth-quarter results, expected Feb. 2, 2027.** The estimates are EPS of 1.9 and revenue of $16.54B. Both are below this quarter's actuals. Management expects part of the purchase-timing benefit to unwind in the fourth quarter.
- **The 2027 outlook.** Watch whether management's expectation of "moderate top line growth" holds and how the higher spending shows up in margins.
- **The pipeline.** Davis said the company's long-term revenue opportunity figure will be raised, citing items not previously counted, including the Prometheus acquisition and PD-1/VEGF upside.
- **The Dutch court proceedings** and any spread of the QLEX injunction.
- **Cash flow.** Whether free cash flow stays above the year-ago level once the third-quarter 2026 cash flow statement is available.

## Frequently asked questions

## Q: Did Merck beat earnings estimates in the third quarter of 2026?

Yes. For the quarter ended Sept. 30, 2026, Merck reported adjusted EPS of 2.49 against an estimate of 2.09, and revenue of $18.09B against an estimate of $17.33B. Revenue was 5.2% above the year-ago quarter, but net income of $5.07B was 12.4% lower than a year earlier.

## Q: Why were Merck's earnings negative earlier in 2026 but positive now?

Merck posted net losses in the quarters ended March 31, 2026 and June 30, 2026, even though revenue held near $16B per quarter. Gross margin stayed high, so the losses came from items below gross profit rather than weak sales. The company did not give a single explanation on the call, so check its filings for the specific drivers. Operating margin recovered to 40.6% in the quarter ended Sept. 30, 2026.

## Q: Is Merck stock expensive after earnings?

That depends on the measure. Trailing P/E of 152.61 is far above peers such as Amgen (29.10) and AstraZeneca (27.94), but it reflects the first-half 2026 losses. Price/free cash flow is 22.97. Analysts' average price target is 159.95 USD against a share price of 149.58 USD on Oct. 30, 2026. This is information, not advice.

*Sources: Stock Expert AI market data (MoonshotScore) and FMP financial data for prices, estimates, ratings and peers; the Merck earnings call of Oct. 29, 2026 for management quotes and guidance. The law-firm item comes from a third-party press release.*


*This is educational content, not investment advice. Past performance does not guarantee future results.*

## Related Tickers
- [MRK](https://www.stockexpertai.com/stock/mrk)

## Sources
- [Stock Expert AI MRK page: quote, financials and MoonshotScore](https://www.stockexpertai.com/stock/mrk)
- [businesswire.com: Lost Money on Merck & Co., Inc. Shares? The Law Offices of Frank R.](https://www.businesswire.com/news/home/20261029257635/en/Lost-Money-on-Merck-Co.-Inc.-Shares-The-Law-Offices-of-Frank-R.-Cruz-Investigates-Potential-Securities-Fraud-After-1.76-Stock-Decline/)
- [247wallst.com: $250,000 in Merck, Pfizer, UnitedHealth and AbbVie Could Pay $8,000 a Year in Dividends](https://247wallst.com/investing/2026/10/30/250000-in-merck-pfizer-unitedhealth-and-abbvie-could-pay-8000-a-year-in-dividends/)
- [247wallst.com: Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up](https://247wallst.com/investing/2026/10/30/regeneron-surges-12-as-sanofi-dupixent-windfall-and-eylea-hd-power-earnings-beat-moderna-slides-2-merck-edges-higher-pfizer-ticks-up/)
- [zacks.com: Merck Q3 Earnings Call Highlights Pipeline Progress and Raised Outlook](https://www.zacks.com/stock/news/3019671/merck-q3-earnings-call-highlights-pipeline-progress-and-raised-outlook?cid=CS-STOCKNEWSAPI-FT-analyst_blog_plus|earnings_call_takeaways-3019671)
- [marketbeat.com: Merck & Co., Inc. Q3 Earnings Call Highlights](https://www.marketbeat.com/instant-alerts/transcript-merck-co-inc-q3-earnings-call-highlights-2026-10-30/)

---
_Written by Stock Expert AI's research desk with AI assistance. Figures come from FMP data and the official sources cited in the article. Educational research, not financial advice._